{"id":416440,"date":"2021-01-19T07:03:28","date_gmt":"2021-01-19T12:03:28","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=416440"},"modified":"2021-01-19T07:03:28","modified_gmt":"2021-01-19T12:03:28","slug":"onl-therapeutics-names-connie-chang-as-chief-operating-officer","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/onl-therapeutics-names-connie-chang-as-chief-operating-officer\/","title":{"rendered":"ONL Therapeutics Names Connie Chang as Chief Operating Officer"},"content":{"rendered":"

\nCompany expands leadership team as it advances lead candidate ONL1204 beyond retinal detachment into the chronic conditions of glaucoma and dry age-related macular degeneration
\n<\/h2>\n
\n

ANN ARBOR, Mich., Jan. 19, 2021 (GLOBE NEWSWIRE) — ONL Therapeutics, Inc., a biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal disease, today announced the appointment of Connie Chang to the newly created position of chief operating officer (COO). As COO, Ms. Chang will lead key operational workstreams, build and integrate internal capabilities, engage with external stakeholders and develop the company\u2019s global strategic plans, working closely with CEO David Esposito.<\/p>\n

\u201cConnie\u2019s broad experience and leadership skills are well aligned with our immediate plans to accelerate the development of our pipeline, enabled by our recent Series B financing,\u201d commented Mr. Esposito. \u201cWith our 2021 plans to complete the Phase 1 study of our lead asset in retinal detachment and to further advance programs for ONL1204 in two additional chronic indications, we welcome Connie to the leadership team as we embark on the critical next stage of ONL\u2019s growth.\u201d<\/p>\n

Last month, ONL announced the closing of a $46.9 million Series B Preferred Stock financing round, led by Fort Worth, TX-based Bios Partners. The Series B funding supports the ongoing Phase 1 clinical study of ONL1204 in retinal detachment, as well as the advancement of the asset into the chronic conditions of glaucoma and dry age-related macular degeneration.<\/p>\n

\u201cI am thrilled to join ONL Therapeutics at this critical inflection point for the company,\u201d said Ms. Chang. \u201cThe potential for ONL\u2019s Fas inhibition platform to bring first-in-class neuroprotection therapies to market and ultimately to help patients suffering from retinal diseases is impressive and compelling, and I look forward to contributing to the company\u2019s mission.\u201d<\/p>\n

Ms. Chang brings to ONL a diverse 25-year career spanning large and small biopharma, early-stage technology commercialization and management consulting. She was most recently vice president of corporate affairs at Millendo Therapeutics where she was responsible for building critical infrastructure as the company became publicly traded, including investor and public relations, facilities and operations, information technology and corporate communications. Previously, she was managing director of Fast Forward Medical Innovation at the University of Michigan Medical School, accelerating university-based biomedical technologies through funding, industry collaboration and entrepreneurial support. Prior to that, Ms. Chang was with Sunovion and Pfizer, leading business teams and commercial strategies across multiple categories such as sleep medicine, allergy\/respiratory, and cardiovascular. She received her bachelor of arts degree in psychobiology from Harvard University and an MBA from Harvard Business School.<\/p>\n

\n About ONL1204<\/strong>\n <\/p>\n

ONL1204 is a novel, first-in-class small molecule Fas inhibitor designed to protect key retinal cells, including photoreceptors, from cell death that occurs in a range of retinal diseases and conditions. Death of these retinal cells, through both direct and inflammatory signaling pathways, is the root cause of vision loss and the leading cause of blindness. The company\u2019s ONL1204 development program focused its first indication on the treatment of retinal detachment, a condition for which the compound has been granted orphan drug designation by the United States Food and Drug Administration (FDA). Clinical trial plans were focused first on the acute indication of retinal detachment, with continuing preclinical work occurring to enable clinical trials in other disease indications, including glaucoma, age-related macular degeneration (AMD), and inherited retinal degeneration (IRD; also known as retinitis pigmentosa).<\/p>\n

\n About ONL Therapeutics<\/strong>\n <\/p>\n

ONL Therapeutics (ONL) is a biopharmaceutical company committed to protecting and improving the vision of patients with retinal disease. By advancing a novel breakthrough technology designed to protect key retinal cells from Fas-mediated cell death, ONL is pioneering an entirely new approach to preserving vision. ONL is developing a platform of products for use in a wide range of blinding diseases, including retinal detachment, glaucoma, AMD, and IRD.<\/p>\n

For more information about ONL Therapeutics, please visit\u00a0www.onltherapeutics.com<\/a>.\u00a0\u00a0<\/p>\n

\n Company Contact:<\/strong>
\n
ONL Therapeutics, Inc.
Linda Kemnitz
lkemnitz@onltherapeutics.com<\/a><\/p>\n

\n
\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

Company expands leadership team as it advances lead candidate ONL1204 beyond retinal detachment into the chronic conditions of glaucoma and dry age-related macular degeneration ANN ARBOR, Mich., Jan. 19, 2021 (GLOBE NEWSWIRE) — ONL Therapeutics, Inc., a biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal disease, today announced the appointment of Connie Chang to the newly created position of chief operating officer (COO). As COO, Ms. Chang will lead key operational workstreams, build and integrate internal capabilities, engage with external stakeholders and develop the company\u2019s global strategic plans, working closely with CEO David Esposito. \u201cConnie\u2019s broad experience and leadership skills are well aligned with our immediate plans to accelerate the development of our pipeline, enabled … <\/p>\n

Continue reading “ONL Therapeutics Names Connie Chang as Chief Operating Officer”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-416440","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nONL Therapeutics Names Connie Chang as Chief Operating Officer - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/onl-therapeutics-names-connie-chang-as-chief-operating-officer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ONL Therapeutics Names Connie Chang as Chief Operating Officer - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Company expands leadership team as it advances lead candidate ONL1204 beyond retinal detachment into the chronic conditions of glaucoma and dry age-related macular degeneration ANN ARBOR, Mich., Jan. 19, 2021 (GLOBE NEWSWIRE) — ONL Therapeutics, Inc., a biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal disease, today announced the appointment of Connie Chang to the newly created position of chief operating officer (COO). As COO, Ms. Chang will lead key operational workstreams, build and integrate internal capabilities, engage with external stakeholders and develop the company\u2019s global strategic plans, working closely with CEO David Esposito. \u201cConnie\u2019s broad experience and leadership skills are well aligned with our immediate plans to accelerate the development of our pipeline, enabled … Continue reading "ONL Therapeutics Names Connie Chang as Chief Operating Officer"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/onl-therapeutics-names-connie-chang-as-chief-operating-officer\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-01-19T12:03:28+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyNjkxMyMzOTIxODAzIzIwOTM3NDI=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/onl-therapeutics-names-connie-chang-as-chief-operating-officer\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/onl-therapeutics-names-connie-chang-as-chief-operating-officer\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"ONL Therapeutics Names Connie Chang as Chief Operating Officer\",\"datePublished\":\"2021-01-19T12:03:28+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/onl-therapeutics-names-connie-chang-as-chief-operating-officer\\\/\"},\"wordCount\":658,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/onl-therapeutics-names-connie-chang-as-chief-operating-officer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyNjkxMyMzOTIxODAzIzIwOTM3NDI=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/onl-therapeutics-names-connie-chang-as-chief-operating-officer\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/onl-therapeutics-names-connie-chang-as-chief-operating-officer\\\/\",\"name\":\"ONL Therapeutics Names Connie Chang as Chief Operating Officer - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/onl-therapeutics-names-connie-chang-as-chief-operating-officer\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/onl-therapeutics-names-connie-chang-as-chief-operating-officer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyNjkxMyMzOTIxODAzIzIwOTM3NDI=\",\"datePublished\":\"2021-01-19T12:03:28+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/onl-therapeutics-names-connie-chang-as-chief-operating-officer\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/onl-therapeutics-names-connie-chang-as-chief-operating-officer\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/onl-therapeutics-names-connie-chang-as-chief-operating-officer\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyNjkxMyMzOTIxODAzIzIwOTM3NDI=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyNjkxMyMzOTIxODAzIzIwOTM3NDI=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/onl-therapeutics-names-connie-chang-as-chief-operating-officer\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ONL Therapeutics Names Connie Chang as Chief Operating Officer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ONL Therapeutics Names Connie Chang as Chief Operating Officer - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/onl-therapeutics-names-connie-chang-as-chief-operating-officer\/","og_locale":"en_US","og_type":"article","og_title":"ONL Therapeutics Names Connie Chang as Chief Operating Officer - Market Newsdesk","og_description":"Company expands leadership team as it advances lead candidate ONL1204 beyond retinal detachment into the chronic conditions of glaucoma and dry age-related macular degeneration ANN ARBOR, Mich., Jan. 19, 2021 (GLOBE NEWSWIRE) — ONL Therapeutics, Inc., a biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal disease, today announced the appointment of Connie Chang to the newly created position of chief operating officer (COO). As COO, Ms. Chang will lead key operational workstreams, build and integrate internal capabilities, engage with external stakeholders and develop the company\u2019s global strategic plans, working closely with CEO David Esposito. \u201cConnie\u2019s broad experience and leadership skills are well aligned with our immediate plans to accelerate the development of our pipeline, enabled … Continue reading \"ONL Therapeutics Names Connie Chang as Chief Operating Officer\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/onl-therapeutics-names-connie-chang-as-chief-operating-officer\/","og_site_name":"Market Newsdesk","article_published_time":"2021-01-19T12:03:28+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyNjkxMyMzOTIxODAzIzIwOTM3NDI=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/onl-therapeutics-names-connie-chang-as-chief-operating-officer\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/onl-therapeutics-names-connie-chang-as-chief-operating-officer\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"ONL Therapeutics Names Connie Chang as Chief Operating Officer","datePublished":"2021-01-19T12:03:28+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/onl-therapeutics-names-connie-chang-as-chief-operating-officer\/"},"wordCount":658,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/onl-therapeutics-names-connie-chang-as-chief-operating-officer\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyNjkxMyMzOTIxODAzIzIwOTM3NDI=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/onl-therapeutics-names-connie-chang-as-chief-operating-officer\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/onl-therapeutics-names-connie-chang-as-chief-operating-officer\/","name":"ONL Therapeutics Names Connie Chang as Chief Operating Officer - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/onl-therapeutics-names-connie-chang-as-chief-operating-officer\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/onl-therapeutics-names-connie-chang-as-chief-operating-officer\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyNjkxMyMzOTIxODAzIzIwOTM3NDI=","datePublished":"2021-01-19T12:03:28+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/onl-therapeutics-names-connie-chang-as-chief-operating-officer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/onl-therapeutics-names-connie-chang-as-chief-operating-officer\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/onl-therapeutics-names-connie-chang-as-chief-operating-officer\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyNjkxMyMzOTIxODAzIzIwOTM3NDI=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyNjkxMyMzOTIxODAzIzIwOTM3NDI="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/onl-therapeutics-names-connie-chang-as-chief-operating-officer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"ONL Therapeutics Names Connie Chang as Chief Operating Officer"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/416440","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=416440"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/416440\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=416440"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=416440"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=416440"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}